Hematologist-oncologist Sergio Giralt was interviewed about treating Good Morning America co-host Robin Roberts, who received a stem cell transplant at Memorial Sloan-Kettering.
Medical oncologist Leonard Saltz and epidemiologist Peter Bach commented on Memorial Sloan-Kettering’s decision not to carry a new colorectal cancer drug due to its cost.
Director of Memorial Sloan-Kettering’s Male Sexual and Reproductive Medicine Program John Mulhall discussed ways to improve sexual function after prostate cancer surgery.
Medical oncologist Larry Norton discussed cancer advances made possible by collaborative efforts like those described in a recent TIME magazine article.
Medical oncologist Renier Brentjens was interviewed about a study he co-led with cell researcher Michel Sadelain that found that genetically modified immune cells were able to induce complete remissions in patients with advanced B cell acute lymphoblastic leukemia.
Medical oncologist Renier Brentjens and cell researcher Michel Sadelain reported for the first time that genetically modified immune cells were able to induce complete remissions in all five patients treated with the experimental therapy. Patients had advanced B cell acute lymphoblastic leukemia, a disease with limited treatment options.
Medical oncologist Howard Scher commented on an investigational microchip that can count and sort cancer cells so doctors can determine how well treatments are working.
Epidemiologist Talya Salz commented on a study that found that women experience significant stress when called for follow-up after a routine mammogram, and that the stress lasts long after follow-up tests show no signs of cancer.
Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific proteins on cancer cells. The new monoclonal antibody, called ESK1, is different because it is capable of recognizing the presence of a protein inside cancer cells, not just on the surface.
Surgical pathologist Jorge Reis-Filho commented on a study that found that an experimental blood test could help identify whether women with advanced breast cancer are responding to treatment.
Memorial Sloan-Kettering’s Green Team, a committee established in 2009 to identify opportunities to reduce waste and conserve resources, effectively reduced energy costs in operating rooms by disabling air exchanges when the rooms are not in use.
Epidemiologist Colin Begg commented on a study that suggests that cancer patients on clinical trials may survive longer due to factors other than the treatment being studied.
Adam Cohen, Memorial Sloan-Kettering’s Assistant General Counsel and Manager of Immigration Services, commented on a report that found that more than 40 percent of the cancer researchers at America’s top cancer institutes are immigrants.
Deputy Physician-in-Chief for Clinical Research Paul Sabbatini commented on the ways targeted drugs are able to move through the approval process more quickly than other types of drugs.
